• BioMarin to acquire Dimerix's US commercial licensing partner Amicus Therapeutics
• Transaction valued at ~$7.25 billion AUD
• Dimerix remains eligible for up to $940 million in milestone payments plus royalties

Dimerix Limited, a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, has announced that BioMarin Pharmaceutical has entered into a definitive agreement to acquire its US commercial licensing partner, Amicus Therapeutics, in an all-cash transaction valued at approximately $4.8 billion USD (~$7.25 billion AUD). Upon closing of the transaction, BioMarin's acquisition will include the Dimerix commercial licensing contract, including all rights and obligations currently held by Amicus. The commercial licensing agreement remains in full force and effect, and until the closing of the transaction, Amicus and Dimerix will continue to collaborate on planning for DMX-200 in the U.S. Under the commercial licensing Agreement between Dimerix and Amicus, Dimerix remains eligible to receive up to $590 million (~$940 million AUD) in upfront, development, and sales milestone payments, plus royalties. Dimerix's license deals with territories outside the US, including Advanz Pharma, Taiba, and Fuso, remain unaffected. Collectively, the four license deals provide up to ~$1.4 billion AUD in total upfront payments and potential milestone payments, plus royalties on net sales, with over $65 million in total payments received to date. Dimerix remains well positioned to continue focusing on advancing the ACTION3 Phase 3 clinical trial for its DMX-200 product candidate, as well as licensing opportunities with potential partners in territories not already licensed.

Dimerix remains well positioned to continue focusing on advancing the ACTION3 Phase 3 clinical trial for its DMX-200 product candidate, as well as licensing opportunities with potential partners in territories not already licensed.